A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women

An Open-label, Single Dose Study to Evaluate Lemborexant in Milk of Healthy Lactating Women

The primary purpose of the study is to estimate the cumulative amount of lemborexant excreted in breast milk following a single dose administration of lemborexant 10 milligram (mg) to healthy lactating women and to estimate the relative infant dose (RID) expressed as a percent of the daily maternal dose.

Study Overview

• Status: Completed
• Conditions: Healthy Volunteers
• Intervention / Treatment: Drug: Lemborexant

• Study Type: Interventional
• Enrollment (Actual): 8
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Nevada
    • Las Vegas, Nevada, United States, 89113
      • PPD Phase 1 Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Is a healthy lactating female at least 18 years of age and willing to sign an informed consent prior to any study-related activities.
2. The participant must have had a normal term pregnancy and has been actively breastfeeding or pumping for at least 5 weeks postpartum; lactation must be well-established and the mother not experiencing problems with feeding her infant breast milk. Participants planning on weaning their infants independent of study participation, who meet aforementioned requirements, will be considered for enrolment in the study.
3. Is willing not to breastfeed for 11 days after the study drug administration.
4. Breastfeeds an infant who is already able to feed from a bottle.
5. Agrees to collect all breast milk from predose to end of the study using an electric pump provided by the sponsor.
6. Is considered reliable and capable of adhering to the protocol and visit schedule according to the judgment of the investigator.

Exclusion Criteria:

1. Has a positive pregnancy test at Screening or Baseline.
2. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; example, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism.
3. Any history of gastrointestinal surgery that may affect pharmacokinetic (PK) profiles, example, hepatectomy, nephrectomy, digestive organ resection (but not cholecystectomy) at Screening or Baseline.
4. Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, ECG finding, or laboratory test results that require medical treatment at Screening or Baseline.
5. A prolonged QT interval by Fridericia (QTcF) (QTcF greater than [>] 450 milliseconds [ms]) as demonstrated by a repeated ECG at Screening.
6. Any suicidal behavior (per the Suicidal Behavior section of the Columbia-Suicide Severity Rating Scale) within 10 years of Screening.
7. Evidence of clinically significant disease (example, cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator(s) could affect the participant's safety or interfere with the study assessments.
8. Exposure within the last 14 days to an individual with confirmed or probable coronavirus disease (COVID-19) or symptoms within the last 14 days that are on the most recent centers for disease control and prevention (CDC) list of COVID symptoms or any other reason to consider the participant at potential risk for an acute COVID-19 infection.
9. Has mastitis or other condition that would prevent the collection of milk from one or both breasts.
10. Is a smoker (>5 cigarettes, or nicotine equivalent, per day).
11. Has a positive result for urine drug screening.
12. Has undergone surgery (other than caesarean section) or donated blood within 8 weeks prior to the start of the study.
13. Used any prescription or over-the-counter medications, which may impact plasma concentration of lemborexant, within 1 week or 5 half-lives, whichever is longer, before Screening.
14. Hypersensitivity to the study drug or any of the excipients.
15. History of or has concomitant medical condition(s) that in the opinion of the investigator(s) would compromise the participant's ability to safely complete the study.
16. History of drug or alcohol dependency or abuse within approximately the last 2 years.
17. Currently enrolled in another clinical study or used any investigational drug or device within 28 days or 5*the half-life, whichever is longer preceding informed consent.
18. Known to be human immunodeficiency virus (HIV) positive at Screening.
19. Active viral hepatitis (B or C) as demonstrated by positive serology at Screening.
20. Has a current or prior diagnosis of narcolepsy.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Lemborexant 10 mg; Participants will receive a single dose of lemborexant 10 mg tablet, orally on Day 1.	Drug: Lemborexant; Lemborexant oral tablets.; Other Names: E2006; Dayvigo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ae: Cumulative Total (Unchanged) Amount of Lemborexant Excreted in Breast Milk Over the Entire Collection		0-240 hours post-dose
Fraction (Percentage) of Dose Excreted in Breast Milk	Fraction of dose excreted will be calculated as: Ae/Administered dose.	0-240 hours post-dose
RID: Relative Infant Dose	Relative infant dose is defined as the infant drug exposure via breast milk which is the body weight-adjusted percentage of maternal dose. Relative infant dose will be calculated by the formula: Daily infant dose milligram per kilogram (mg/kg)/maternal dose (mg/kg)*100, where estimated daily infant dose is as per the Food and Drug Administration (FDA) guidance (2019). Daily infant dose (mg/kg) = Ae/weight of infant.	0-240 hours post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs)		Up to 215 days
Number of Participants Reporting one or More TEAEs Based on Severity	All TEAEs will be graded on a 3-point scale (mild, moderate, and severe). The definitions are as follows: Mild (Discomfort noticed, but no disruption of normal daily activity); Moderate (Discomfort sufficient to reduce or affect normal daily activity); Severe (Incapacitating, with inability to work or to perform normal daily activity).	Up to 215 days
Number of Participants Reporting one or More TEAEs Based on Dose-relationship of Adverse Events (AEs)		Up to 215 days
Number of Participants With Clinically Significant Change in 12-lead Electrocardiogram (ECG) Findings		Up to 215 days
Number of Participants With Clinically Significant Change From Baseline in Vital Sign Values		Baseline up to 215 days
Number of Participants With Markedly Abnormal Change From Baseline in Laboratory Parameters		Baseline up to 215 days

Collaborators and Investigators

• Sponsor: Eisai Inc.

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 17, 2021
• Primary Completion (ACTUAL): August 12, 2021
• Study Completion (ACTUAL): August 12, 2021

Study Registration Dates

• First Submitted: May 13, 2021
• First Submitted That Met QC Criteria: May 13, 2021
• First Posted (ACTUAL): May 18, 2021

Study Record Updates

• Last Update Posted (ACTUAL): September 5, 2021
• Last Update Submitted That Met QC Criteria: September 2, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Hypnotics and Sedatives; Sleep Aids, Pharmaceutical; Orexin Receptor Antagonists; Lemborexant
• Other Study ID Numbers: E2006-A001-010

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No